Cheolwon Suh

13.1k total citations
413 papers, 7.8k citations indexed

About

Cheolwon Suh is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Cheolwon Suh has authored 413 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 260 papers in Pathology and Forensic Medicine, 249 papers in Oncology and 84 papers in Genetics. Recurrent topics in Cheolwon Suh's work include Lymphoma Diagnosis and Treatment (254 papers), Viral-associated cancers and disorders (116 papers) and CNS Lymphoma Diagnosis and Treatment (74 papers). Cheolwon Suh is often cited by papers focused on Lymphoma Diagnosis and Treatment (254 papers), Viral-associated cancers and disorders (116 papers) and CNS Lymphoma Diagnosis and Treatment (74 papers). Cheolwon Suh collaborates with scholars based in South Korea, United States and Japan. Cheolwon Suh's co-authors include Dok Hyun Yoon, Jooryung Huh, Won Seog Kim, Dae Ho Lee, Seok Jin Kim, Jin Seok Kim, Young Wha Koh, Chan-Sik Park, Kihyun Kım and Young Hyeh Ko and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Cheolwon Suh

392 papers receiving 7.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Cheolwon Suh 4.7k 4.7k 1.6k 1.5k 1.2k 413 7.8k
David J. Inwards 4.4k 0.9× 3.8k 0.8× 1.7k 1.1× 865 0.6× 2.1k 1.8× 265 8.0k
Michael Crump 5.6k 1.2× 5.3k 1.1× 1.2k 0.8× 1.4k 1.0× 2.4k 2.0× 310 9.8k
Won Seog Kim 7.1k 1.5× 6.3k 1.3× 3.0k 1.9× 999 0.7× 1.8k 1.5× 462 10.8k
Nicolas Mounier 6.1k 1.3× 4.5k 1.0× 1.3k 0.8× 852 0.6× 2.0k 1.7× 207 8.3k
Fredrick B. Hagemeister 6.1k 1.3× 4.3k 0.9× 1.1k 0.7× 1.2k 0.8× 2.7k 2.3× 257 8.5k
Michele Ghielmini 6.5k 1.4× 4.5k 1.0× 1.5k 0.9× 730 0.5× 3.1k 2.6× 134 8.8k
Massimo Federico 8.0k 1.7× 5.5k 1.2× 1.3k 0.8× 2.5k 1.7× 2.1k 1.8× 288 12.0k
Philippe Solal‐Céligny 4.5k 1.0× 4.3k 0.9× 1.9k 1.2× 832 0.6× 2.7k 2.3× 109 8.7k
Jan Walewski 4.6k 1.0× 4.2k 0.9× 913 0.6× 736 0.5× 1.9k 1.7× 214 7.0k
Jorge Romaguera 7.1k 1.5× 5.4k 1.1× 1.2k 0.8× 1.3k 0.9× 3.3k 2.8× 281 9.8k

Countries citing papers authored by Cheolwon Suh

Since Specialization
Citations

This map shows the geographic impact of Cheolwon Suh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheolwon Suh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheolwon Suh more than expected).

Fields of papers citing papers by Cheolwon Suh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheolwon Suh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheolwon Suh. The network helps show where Cheolwon Suh may publish in the future.

Co-authorship network of co-authors of Cheolwon Suh

This figure shows the co-authorship network connecting the top 25 collaborators of Cheolwon Suh. A scholar is included among the top collaborators of Cheolwon Suh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheolwon Suh. Cheolwon Suh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bae, Mi Hyun, Chan‐Jeoung Park, & Cheolwon Suh. (2021). Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma. Journal of Clinical Medicine. 10(20). 4717–4717. 13 indexed citations
2.
Song, Ga‐Young, Dok Hyun Yoon, Cheolwon Suh, et al.. (2020). Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplantation. 56(5). 1205–1208. 10 indexed citations
3.
Lee, Min Young, Chan‐Jeoung Park, Young‐Uk Cho, et al.. (2020). Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma. Annals of Laboratory Medicine. 41(3). 259–267. 3 indexed citations
4.
Kim, Seok Jin, Dok Hyun Yoon, Hye Jin Kang, et al.. (2019). Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer. 19(1). 20 indexed citations
5.
Park, Chan‐Jeoung, Young‐Uk Cho, Seongsoo Jang, et al.. (2019). Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia. Annals of Laboratory Medicine. 40(3). 193–200. 4 indexed citations
6.
Kim, Won Seog, Cheolwon Suh, Jung Yong Hong, et al.. (2019). A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). Leukemia & lymphoma. 60(13). 3251–3257. 4 indexed citations
7.
8.
9.
Suh, Cheolwon, et al.. (2017). Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL. Blood. 130. 5231–5231. 2 indexed citations
10.
Lee, Min Young, Chan‐Jeoung Park, Young‐Uk Cho, et al.. (2017). Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma. Blood. 130. 4400–4400. 2 indexed citations
11.
Roh, Jin, Su‐Jin Shin, Dok Hyun Yoon, et al.. (2016). RGS1 expression is associated with poor prognosis in multiple myeloma. Journal of Clinical Pathology. 70(3). 202–207. 29 indexed citations
12.
Oh, Sung Yong, Won Seog Kim, Jin Seok Kim, et al.. (2015). A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia & lymphoma. 57(6). 1406–1412. 4 indexed citations
13.
Lim, Ji‐Hun, Eul‐Ju Seo, Chan‐Jeoung Park, et al.. (2013). Cytogenetic classification in K orean multiple myeloma patients: prognostic significance of hyperdiploidy with 47–50 chromosomes and the number of structural abnormalities. European Journal Of Haematology. 92(4). 313–320. 13 indexed citations
14.
Yoon, Dok Hyun, Sora Baek, Chang‐Min Choi, et al.. (2011). FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy. Clinical Cancer Research. 17(15). 5093–5100. 13 indexed citations
15.
Koo, Ja Eun, Danbi Lee, Eun Hee Kim, et al.. (2007). Primary gastrointestinal diffuse large B-cell lymphoma: A clinical analysis of 76 patients with special application of International Prognostic Index for survival. The Korean Journal of Internal Medicine. 72(1). 11–19.
16.
Kim, Seok Jin, Hyo Jin Lee, Hawk Kim, et al.. (2007). Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. Blood. 110(11). 4843–4843.
17.
Lee, D.H., Cheolwon Suh, Jeong Hyun Lee, et al.. (2007). Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Annals of Oncology. 19(1). 123–127. 42 indexed citations
18.
Kim, Hyun‐Woo, et al.. (2005). A case of plasmablastic lymphoma in the nasal cavity in a human immunodeficiency virus-negative patient. The Korean Journal of Internal Medicine. 69(4). 446–450.
19.
Sohn, Hee-Jung, Eun-Kyung Kim, Gyeong‐Won Lee, et al.. (2003). Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia. Blood Research. 38(1). 1–7.
20.
Huh, Jooryung, et al.. (2003). 소장 및 대장에서 발생한 원발성 장 림프종. Journal of the Korean Surgical Society. 65(2). 113–118. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David J. Inwards Breakdown of academic impact, for papers by Michael Crump Breakdown of academic impact, for papers by Won Seog Kim Breakdown of academic impact, for papers by Nicolas Mounier Breakdown of academic impact, for papers by Fredrick B. Hagemeister Breakdown of academic impact, for papers by Michele Ghielmini Breakdown of academic impact, for papers by Massimo Federico Breakdown of academic impact, for papers by Philippe Solal‐Céligny Breakdown of academic impact, for papers by Jan Walewski Breakdown of academic impact, for papers by Jorge Romaguera
Rankless by CCL
2026